Abstract
Completion of treatment for tuberculosis infection (TBI) with 9 months of self-administered daily isoniazid (9H) has historically been low (<50%) among New York City (NYC) Health Department tuberculosis clinic patients. Treatment of TBI with 3 months of once-weekly isoniazid and rifapentine (3HP) administered under directly observed therapy (DOT) might increase treatment acceptance and completion. The study population included patients diagnosed with TBI at 2 NYC Health Department tuberculosis clinics from January 2013 through November 2013. Treatment acceptance and completion with 3HP were compared with historical estimates. Treatment outcomes, side effects, and reasons for refusing 3HP were described. Among 631 patients eligible for TBI treatment, 503 (80%) were offered 3HP; 302 (60%) accepted, 92 (18%) chose other treatment, and 109 (22%) refused treatment. The most common reason for refusing 3HP was the clinic-based DOT requirement. Forty (13%) patients treated with 3HP experienced side effects--9 were restarted on 3HP, 18 switched treatment regimens, and 13 discontinued. Although treatment acceptance did not differ from historical estimates (78% vs 79%, P = .75), treatment completion increased significantly (65% vs 34%, P ...Continue Reading
References
Apr 28, 1994·The New England Journal of Medicine·S E WeisB H Foresman
Feb 25, 1993·The New England Journal of Medicine·G J Annas
Apr 14, 2000·American Journal of Respiratory and Critical Care Medicine
Oct 4, 2000·Child Development
May 15, 2003·American Journal of Respiratory and Critical Care Medicine·Philip A LoBue, Kathleen S Moser
Aug 7, 2009·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Jiehui LiMarie Dorsinville
Dec 14, 2011·The New England Journal of Medicine·Timothy R SterlingUNKNOWN TB Trials Consortium PREVENT TB Study Team
Dec 14, 2011·BMC Public Health·Mesele MindachewSibhatu Biadgilign
Mar 15, 2013·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·P W ColsonUNKNOWN Tuberculosis Epidemiologic Studies Consortium
Nov 10, 2013·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·D ShepardsonW R Mac Kenzie
Feb 6, 2014·PloS One·Titilola MakanjuolaAndrew Booth
Mar 4, 2015·Open Forum Infectious Diseases·Natalie L StennisTiffany G Harris
Citations
Oct 21, 2016·Open Forum Infectious Diseases·Aliya YaminRussell R Kempker
Jan 13, 2017·Critical Reviews in Analytical Chemistry·Guilherme Felipe Dos Santos FernandesJean Leandro Dos Santos
Mar 25, 2018·Pharmacoepidemiology and Drug Safety·Christopher PeaseGonzalo G Alvarez
May 7, 2019·Public Health Reports·Charlotte Wheeler, Janet Mohle-Boetani
May 8, 2020·International Journal of Circumpolar Health·G G AlvarezA Zwerling
Jun 17, 2016·Transplantation·Laura Muñoz, Miguel Santin
Mar 2, 2017·Canada Communicable Disease Report = Relevé Des Maladies Transmissibles Au Canada·C PeaseG G Alvarez
Nov 22, 2018·Journal of Medical Internet Research·Chee Kin LamMichelle Macaraig
Oct 1, 2019·AIDS·Emily A KendallUNKNOWN THRio and TEKO teams
Oct 12, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Esther Arguello PerezArthur E Brown
Jan 28, 2021·Military Medicine·Megan L DonahueMichael Rajnik
May 15, 2021·BMJ Open·Christopher PeaseAlice Zwerling
Jul 2, 2021·Implementation Science Communications·Fred C SemitalaAnne R Katahoire
Oct 13, 2019·Respiratory Medicine·Kyung-Wook JoTae Sun Shim